c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
Jieun ParkEun Sol ChangJi-Yeon KimChaithanya ChelakkotMinjung SungJi-Young SongKyungsoo JungJi Hye LeeJun Young ChoiNa Young KimHyegyeong LeeMi-Ran KangMi Jeong KwonYoung Kee ShinYeon Hee ParkYoon-La ChoiPublished in: Breast cancer research : BCR (2024)
Monitoring c-MET+ CTC, rather than assessing c-MET expression in the primary BC site, could provide valuable information for predicting disease progression, as c-MET expression can change during treatment. The c-MET+ CTC count and cfDNA concentration could provide complementary information on disease progression in HR+ /HER2- mBC, highlighting the importance of integrated liquid biopsy.